WEST DES MOINES, IA--(Marketwired - Jun 10, 2016) - Spotlight Innovation Inc. (
Paul Reid, PhD, Spotlight Innovation's Director of Product Development, said, "As we continue to move forward with our pre-clinical and clinical trials, the opportunity to be based in a state-of-the-art, first-in-class processing facility will offer us consistency and greater efficiency in the production and delivery of clinical samples, and future manufacturing capability."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (
Forward Looking Statements
Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the potential failure to enter into the agreement with Maitland Labs, the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contact Information:
Press Contact
Rene Erickson
Spotlight Innovation Inc.
1-515-274-9087
corpcomm@spotlightinnovation.com
Investor Contact
Bob Woods
CEOcast, Inc.
1-212-732-4300
rwoods@ceocast.com